BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Liver cancer AND PRKACA, MGC48865, 5566, ENSG00000072062, P17612, PKACA, MGC102831 AND Prognosis
9 results:

  • 1. FBXO28 suppresses liver cancer invasion and metastasis by promoting PKA-dependent SNAI2 degradation.
    Qiao X; Lin J; Shen J; Chen Y; Zheng L; Ren H; Zhao X; Yang H; Li P; Wang Z
    Oncogene; 2023 Sep; 42(39):2878-2891. PubMed ID: 37596321
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Exploring the molecular pathogenesis, diagnosis and treatment of fibrolamellar hepatocellular carcinoma: A state of art review of the current literature.
    Alshareefy Y; Shen CY; Prekash RJ
    Pathol Res Pract; 2023 Aug; 248():154655. PubMed ID: 37429175
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. LncRNA THEMIS2-211, a tumor-originated circulating exosomal biomarker, promotes the growth and metastasis of hepatocellular carcinoma by functioning as a competing endogenous RNA.
    Yao J; Hua X; Shi J; Hu X; Lui K; He K; Mai J; Lan T; Lu M
    FASEB J; 2022 Apr; 36(4):e22238. PubMed ID: 35224785
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. DNAJB1-prkaca in HEK293T cells induces LINC00473 overexpression that depends on PKA signaling.
    Kim SS; Kycia I; Karski M; Ma RK; Bordt EA; Kwan J; Karki A; Winter E; Aktas RG; Wu Y; Emili A; Bauer DE; Sethupathy P; Vakili K
    PLoS One; 2022; 17(2):e0263829. PubMed ID: 35167623
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. BAP1 mutations define a homogeneous subgroup of hepatocellular carcinoma with fibrolamellar-like features and activated PKA.
    Hirsch TZ; Negulescu A; Gupta B; Caruso S; Noblet B; Couchy G; Bayard Q; Meunier L; Morcrette G; Scoazec JY; Blanc JF; Amaddeo G; Nault JC; Bioulac-Sage P; Ziol M; Beaufrère A; Paradis V; Calderaro J; Imbeaud S; Zucman-Rossi J
    J Hepatol; 2020 May; 72(5):924-936. PubMed ID: 31862487
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Fibrolamellar Carcinoma: What Is New and Why It Matters.
    Graham RP
    Surg Pathol Clin; 2018 Jun; 11(2):377-387. PubMed ID: 29751881
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Emerging molecular therapeutic targets for cholangiocarcinoma.
    Rizvi S; Gores GJ
    J Hepatol; 2017 Sep; 67(3):632-644. PubMed ID: 28389139
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Fibrolamellar carcinoma: A histologically unique tumor with unique molecular findings.
    Graham RP; Torbenson MS
    Semin Diagn Pathol; 2017 Mar; 34(2):146-152. PubMed ID: 28110996
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. A genomic case study of mixed fibrolamellar hepatocellular carcinoma.
    Griffith OL; Griffith M; Krysiak K; Magrini V; Ramu A; Skidmore ZL; Kunisaki J; Austin R; McGrath S; Zhang J; Demeter R; Graves T; Eldred JM; Walker J; Larson DE; Maher CA; Lin Y; Chapman W; Mahadevan A; Miksad R; Nasser I; Hanto DW; Mardis ER
    Ann Oncol; 2016 Jun; 27(6):1148-1154. PubMed ID: 27029710
    [TBL] [Abstract] [Full Text] [Related]  


    of 1.